February 1, 2023: GSK and Novartis report earnings

GSK and Novartis report earnings
Amgen adopts a two-price technique for Humira’s first biosimilar, Amjevita
Anticipated legislative hurdles for biopharma in 2023
Bayer below strain from buyers to hurry up CEO change

*Please scroll down for the most recent information*

Stay up to date with the latest coronavirus news related to the pharmaceutical industry on our new page

As we speak’s hottest searches:

#February #GSK #Novartis #report #earnings

Leave a Reply

Your email address will not be published. Required fields are marked *